226 related articles for article (PubMed ID: 37191586)
1. MASP2 inhibition by narsoplimab suppresses endotheliopathies characteristic of transplant-associated thrombotic microangiopathy: in vitro and ex vivo evidence.
Elhadad S; Redmond D; Huang J; Tan A; Laurence J
Clin Exp Immunol; 2023 Jul; 213(2):252-264. PubMed ID: 37191586
[TBL] [Abstract][Full Text] [Related]
2. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
[TBL] [Abstract][Full Text] [Related]
3. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
4. Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy.
Khaled SK; Claes K; Goh YT; Kwong YL; Leung N; Mendrek W; Nakamura R; Sathar J; Ng E; Nangia N; Whitaker S; Rambaldi A;
J Clin Oncol; 2022 Aug; 40(22):2447-2457. PubMed ID: 35439028
[TBL] [Abstract][Full Text] [Related]
5. Narsoplimab for severe transplant-associated thrombotic microangiopathy.
Pandrowala A; Ganatra P; Krishnan VP; Sharma AN; Chavan S; Bodhanwala M; Agarwal B; Hiwarkar P
Thromb J; 2023 Mar; 21(1):26. PubMed ID: 36915123
[TBL] [Abstract][Full Text] [Related]
6. Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab.
Rambaldi A; Gritti G; Micò MC; Frigeni M; Borleri G; Salvi A; Landi F; Pavoni C; Sonzogni A; Gianatti A; Binda F; Fagiuoli S; Di Marco F; Lorini L; Remuzzi G; Whitaker S; Demopulos G
Immunobiology; 2020 Nov; 225(6):152001. PubMed ID: 32943233
[TBL] [Abstract][Full Text] [Related]
7. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
Lazana I
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience.
Castelli M; Micò MC; Grassi A; Algarotti A; Lussana F; Finazzi MC; Rambaldi B; Pavoni C; Rizzuto G; Tebaldi P; Vendemini F; Verna M; Bonanomi S; Biondi A; Balduzzi A; Rambaldi A; Gotti G
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38773280
[TBL] [Abstract][Full Text] [Related]
9. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Zhang R; Zhou M; Qi J; Miao W; Zhang Z; Wu D; Han Y
Front Immunol; 2020; 11():564647. PubMed ID: 33552043
[TBL] [Abstract][Full Text] [Related]
11. Use of Eculizumab in Pediatric Patients with High-Risk Transplantation-Associated Thrombotic Microangiopathy: Outcomes and Risk Factors Associated with Response and Survival. A Retrospective Study on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC).
Benítez Carabante MI; Bueno D; Alonso García L; López Torija I; Marsal J; Fernandez Navarro JM; Uria Oficialdegui ML; Panesso M; Molina B; Beléndez Bieler C; Palomo P; Pérez Martínez A; Diaz-de-Heredia C
Transplant Cell Ther; 2024 Jun; 30(6):601.e1-601.e13. PubMed ID: 38521410
[TBL] [Abstract][Full Text] [Related]
12. Interferon-complement loop in transplant-associated thrombotic microangiopathy.
Jodele S; Medvedovic M; Luebbering N; Chen J; Dandoy CE; Laskin BL; Davies SM
Blood Adv; 2020 Mar; 4(6):1166-1177. PubMed ID: 32208488
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
14. Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.
Ardissino G; Capone V; Tedeschi S; Porcaro L; Cugno M
Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890144
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab for transplant-associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients.
Rudoni J; Jan A; Hosing C; Aung F; Yeh J
Eur J Haematol; 2018 Sep; 101(3):389-398. PubMed ID: 29920784
[TBL] [Abstract][Full Text] [Related]
16. Early Elevation of Complement Factor Ba Is a Predictive Biomarker for Transplant-Associated Thrombotic Microangiopathy.
Okamura H; Nakamae H; Shindo T; Ohtani K; Hidaka Y; Ohtsuka Y; Makuuchi Y; Kuno M; Takakuwa T; Harada N; Nishimoto M; Nakashima Y; Koh H; Hirose A; Nakamae M; Wakamiya N; Hino M; Inoue N
Front Immunol; 2021; 12():695037. PubMed ID: 34326846
[TBL] [Abstract][Full Text] [Related]
17. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.
Young JA; Pallas CR; Knovich MA
Bone Marrow Transplant; 2021 Aug; 56(8):1805-1817. PubMed ID: 33875812
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment with eculizumab for posterior reversible encephalopathy syndrome due to underlying transplant-associated thrombotic microangiopathy in patients transplanted for sickle cell disease.
Bhunia N; Abu-Arja R; Bajwa RPS; Auletta JJ; Rangarajan HG
Pediatr Blood Cancer; 2019 Oct; 66(10):e27912. PubMed ID: 31264793
[TBL] [Abstract][Full Text] [Related]
19. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation-associated thrombotic microangiopathy accompanied by renal arteriolar C4d deposition.
Sakamoto K; Imamura T; Osone S; Nishimura A; Nishida M; Ishida H; Hosoi H
Pediatr Transplant; 2015 Jun; 19(4):E97-100. PubMed ID: 25735190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]